<subsec_element><subsec_header></subsec_header><slide_intro></slide_intro><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide1.png</sec_img><sec_label>Slide 1.</sec_label><sec_caption></sec_caption><sec_txt><h3> VTE in Cancer: What Do the Latest Data Suggest?</h3></sec_txt><sec_alt_txt>Slide 1.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide2.png</sec_img><sec_label>Slide 2.</sec_label><sec_caption></sec_caption><sec_txt><h3> Risk of Cancer-Associated VTE<sup type="ref">[1-4]</sup></h3><li>	Risk of venous thromboembolism (VTE) is elevated in cancer</li><li>	In general, patients with cancer have a 1:5 chance of developing VTE</li><li>	VTE risk is variable and dependent on a number of factors, including

<ul><li>	Cancer type (site of tumor)</li><li>	Cancer stage</li><li>	Time since diagnosis of cancer</li><li>	Cancer treatment</li></ul></li></sec_txt><sec_alt_txt>Slide 2.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide3.png</sec_img><sec_label>Slide 3.</sec_label><sec_caption></sec_caption><sec_txt><h3> Risk Factors for Cancer-Associated VTE: Cancer Site<sup type="ref">[4]</sup></h3><li>	The predominant risk factor is the location of the primary tumor</li><li>	Overall, gastrointestinal (GI), pancreas, brain, lung, and ovarian cancer induce the highest risks</li><li>	Relatively lower risks are seen in patients with breast or prostate cancer</li></sec_txt><sec_alt_txt>Slide 3.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide4.png</sec_img><sec_label>Slide 4.</sec_label><sec_caption></sec_caption><sec_txt><h3> Risk Factors for Cancer-Associated VTE: Cancer Treatment Modality<sup type="ref">[5]</sup></h3></sec_txt><sec_alt_txt>Slide 4.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide5.png</sec_img><sec_label>Slide 5.</sec_label><sec_caption></sec_caption><sec_txt><h3> Risk Factors for Cancer-Associated VTE: Patient-Related Factors<sup type="ref">[5]</sup></h3><li>	Ethnicity

<ul><li>	Risk greater with African American vs Caucasian vs Asian population</li><li>	Attributed risk, however, is minor</li></ul></li><li>	Compression of major vessels by tumors</li></sec_txt><sec_alt_txt>Slide 5.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide6.png</sec_img><sec_label>Slide 6.</sec_label><sec_caption></sec_caption><sec_txt><h3> Guideline Recommendations: Cancer-Associated VTE Treatment<sup type="ref">[6-8]</sup></h3><li>	Most guidelines recommend monotherapy with low-molecular-weight heparin (LMWH) for at least 6 months</li><li>	Latest data from VTE treatment trials with non-vitamin K antagonist oral anticoagulants (NOACs) are challenging the current treatment paradigm</li></sec_txt><sec_alt_txt>Slide 6.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide7.png</sec_img><sec_label>Slide 7.</sec_label><sec_caption></sec_caption><sec_txt><h3> Challenges With LMWH</h3><li>	LMWHs are injectable agents

<ul><li>	Injectable agents are treated differently in prescription plans and copayment can be high</li><li>	Daily self-injection adds to the burden of treatment</li></ul></li></sec_txt><sec_alt_txt>Slide 7.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide8.png</sec_img><sec_label>Slide 8.</sec_label><sec_caption></sec_caption><sec_txt><h3> Persistence With Anticoagulation for Cancer-Associated VTE<sup type="ref">[9]</sup></h3><li>	Real-world analysis: LMWH was associated with significantly lower persistence and shorter duration of treatment</li></sec_txt><sec_alt_txt>Slide 8.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide9.png</sec_img><sec_label>Slide 9.</sec_label><sec_caption></sec_caption><sec_txt><h3> VTE and Major Bleeding Risk in Patients Receiving Chemotherapy: A Real-World Analysis<sup type="ref">[10]</sup></h3><li>	Patients with cancer are at high risk of both VTE and major bleeding</li><li>	VTE and major bleeding can be fatal</li><li>	Major bleeding can be difficult to treat; especially GI mucosal bleeding</li><li>	Minor (eg, nuisance) bleeding is also common</li></sec_txt><sec_alt_txt>Slide 9.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide10.png</sec_img><sec_label>Slide 10.</sec_label><sec_caption></sec_caption><sec_txt><h3> Treatment of Cancer-Associated VTE: Clinical Trials of NOACs<sup type="ref">[11-13]</sup></h3></sec_txt><sec_alt_txt>Slide 10.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide11.png</sec_img><sec_label>Slide 11.</sec_label><sec_caption></sec_caption><sec_txt><h3> Hokusai VTE-Cancer: Design<sup type="ref">[14]</sup></h3><li>	Study population with active cancer and symptomatic/incidental deep vein thrombosis (DVT) or proximal pulmonary embolism (PE)

<ul><li>	DVT of proximal lower extremity (popliteal, femoral, or iliac vein thrombosis)</li><li>	PE involving segmental or more proximal pulmonary arteries</li></ul></li><li>	All patients were treated for at least 6 months</li><li>	Physicians were encouraged to continue treatment for 12 months</li></sec_txt><sec_alt_txt>Slide 11.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide12.png</sec_img><sec_label>Slide 12.</sec_label><sec_caption></sec_caption><sec_txt><h3> Hokusai VTE-Cancer: Primary Outcome<sup type="ref">[11]</sup></h3><li>	Edoxaban was noninferior to dalteparin</li></sec_txt><sec_alt_txt>Slide 12.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide13.png</sec_img><sec_label>Slide 13.</sec_label><sec_caption></sec_caption><sec_txt><h3> Hokusai VTE-Cancer: Primary Outcome Components<sup type="ref">[11]</sup></h3><li>	Rate of recurrent VTE was significantly lower with edoxaban vs dalteparin</li><li>	Rate of major bleeding was significantly higher with edoxaban vs dalteparin</li><li>	Most major bleeding occurred in patients with GI cancers</li></sec_txt><sec_alt_txt>Slide 13.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide14.png</sec_img><sec_label>Slide 14.</sec_label><sec_caption></sec_caption><sec_txt><h3> SELECT-D: Design<sup type="ref">[15]</sup></h3><li>	Study population similar to Hokusai VTE-Cancer</li></sec_txt><sec_alt_txt>Slide 14.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide15.png</sec_img><sec_label>Slide 15.</sec_label><sec_caption></sec_caption><sec_txt><h3> SELECT-D: Primary Endpoint – Recurrent VTE at 6 Months<sup type="ref">[12]</sup></h3><li>	Rivaroxaban was associated with relatively low VTE recurrence compared with dalteparin</li></sec_txt><sec_alt_txt>Slide 15.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide16.png</sec_img><sec_label>Slide 16.</sec_label><sec_caption></sec_caption><sec_txt><h3> SELECT-D: Major and CRNM Bleeding at 6 Months<sup type="ref">[12]</sup></h3><li>	Rivaroxaban was associated with relatively higher clinically relevant nonmajor (CRNM) bleeding compared with dalteparin</li><li>	Most of the major bleeding occurred in patients with GI cancers</li></sec_txt><sec_alt_txt>Slide 16.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide17.png</sec_img><sec_label>Slide 17.</sec_label><sec_caption></sec_caption><sec_txt><h3> SELECT-D: Major Bleeding by Tumor Type<sup type="ref">[12]</sup></h3><li>	Among GI cancers, most major bleeding was confined to upper GI cancers</li></sec_txt><sec_alt_txt>Slide 17.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide18.png</sec_img><sec_label>Slide 18.</sec_label><sec_caption></sec_caption><sec_txt><h3> Hokusai VTE-Cancer: Major Bleeding by Tumor Type<sup type="ref">[16]</sup></h3><li>	Excess major bleeding with edoxaban was confined to patients with GI cancer</li></sec_txt><sec_alt_txt>Slide 18.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide19.png</sec_img><sec_label>Slide 19.</sec_label><sec_caption></sec_caption><sec_txt><h3> NOACs for Treatment of Cancer Associated VTE: Guidance From ISTH<sup type="ref">[17]</sup></h3><li>	An estimated 60% to 70% of overall cancer population may be eligible for treatment with NOACs</li><li>	In patients with high risk of bleeding, reassess therapy options when bleeding risk changes over time</li><li>	Patients with severe thrombocytopenia are candidates for LMWH

<ul><li>	LMWH can be dose-adjusted based on the platelet count</li><li>	Fine tuning of dose is not currently possible with NOACs</li></ul></li></sec_txt><sec_alt_txt>Slide 19.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide20.png</sec_img><sec_label>Slide 20.</sec_label><sec_caption></sec_caption><sec_txt><h3> Anticoagulation in Cancer Patients With Thrombocytopenia: Guidance From ISTH<sup type="ref">[18]</sup></h3><li>	Option to start with one therapy and switch to another when patient condition improves</li><li>	For example, in patients with GI cancer

<ul><li>	Could start therapy with LMWH</li><li>	If bleeding risk improves, switch to a NOAC</li><li>	If platelet count declines after switching to NOAC, bridge to LMWH until platelet count improves to safely resume NOAC</li></ul></li></sec_txt><sec_alt_txt>Slide 20.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide21.png</sec_img><sec_label>Slide 21.</sec_label><sec_caption></sec_caption><sec_txt><h3> Guidance for Prevention of Cancer-Associated VTE<sup type="ref">[19]</sup></h3><li>	Clinical trials on thromboprophylaxis found benefit in patients with high risk score (Khorana score ≥3)</li><li>	Although thromboprophylaxis is recommended in patients with cancer who are at high risk of VTE, it is not usually followed</li></sec_txt><sec_alt_txt>Slide 21.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide22.png</sec_img><sec_label>Slide 22.</sec_label><sec_caption></sec_caption><sec_txt><h3> CASSINI: Design<sup type="ref">[20]</sup></h3></sec_txt><sec_alt_txt>Slide 22.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide23.png</sec_img><sec_label>Slide 23.</sec_label><sec_caption></sec_caption><sec_txt><h3> AVERT: Design<sup type="ref">[21]</sup></h3></sec_txt><sec_alt_txt>Slide 23.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide24.png</sec_img><sec_label>Slide 24.</sec_label><sec_caption></sec_caption><sec_txt><h3> Summary</h3></sec_txt><sec_alt_txt>Slide 24.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide25.png</sec_img><sec_label>Slide 25.</sec_label><sec_caption></sec_caption><sec_txt><h3> Summary (cont)</h3></sec_txt><sec_alt_txt>Slide 25.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide26.png</sec_img><sec_label>Slide 26.</sec_label><sec_caption></sec_caption><sec_txt><h3> Thank you</h3></sec_txt><sec_alt_txt>Slide 26.</sec_alt_txt><qna_form></qna_form></slide_grp><qna_form></qna_form></subsec_element>